What Retatrutide is
Retatrutide is an investigational triple agonist designed to engage GLP-1, GIP, and glucagon receptor pathways.
Retatrutide is grouped under Fat Loss + GLP-1s on PeptideFactCheck because it is one of the most watched next-generation metabolic peptides because of early weight-loss trial results and online demand.
The useful starting point is to separate the molecule itself from the internet story around it. It is hyped because it targets GLP-1, GIP, and glucagon receptor pathways.
Why people keep looking it up
People are watching retatrutide as a next-generation weight-loss peptide.
Retatrutide is designed as a triple agonist that pushes several metabolic signaling pathways at once.
Retatrutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, gip receptor, and glucagon receptor. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
It is investigational. Early human data can be exciting without being the same as approval.
Human clinical trials exist, but it is not the same category as an approved medicine.
Mechanistic rationale comes from incretin and glucagon receptor biology.
Why this page carries the current tier: Promising early human data with investigational status and heightened marketing risk.
The current seed trail for Retatrutide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Long-term outcomes, approved labeling, manufacturing quality outside trials, and off-trial product claims remain unresolved.
Retatrutide is not an FDA-approved drug in this V1 source trail. FDA has warned about unapproved GLP-1 related products marketed for research or human use.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Retatrutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Retatrutide is CID 171390338. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 171390338
- Formula
- C221H342N46O68
- Molecular weight
- 4731
- InChIKey
- MLOLQJNKXBNWFW-SAGGEDDASA-N
Matched synonyms include Retatrutide, 2381089-83-2, LY3437943, GTPL13769, Triple G, orb1981169, EX-A7826E, LY-3437943.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Retatrutide returns 32 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Retatrutide returns 138 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Esokalli Slimming microcrystalline patch
- Generic names
- ESOKALLI SLIMMING MICROCRYSTALLINE PATCH
- Routes
- TOPICAL
- Application numbers
- 505G(a)(3)
Indications and usage. Uses To support weight management To improve glycemic control in adults with type 2 diabetes mellitus Provides long-acting sustained-release delivery via soluble microneedle patch
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.